FL116 / Forlong Biotech - LARVOL DELTA

FL116, a PD-1/IL-18 bispecific antibody, enables cis-activation of PD-1⁺ T cells and reshapes the suppressive tumor microenvironment (TME) (AACR 2026) - "FL116 achieves potent antitumor activities, high CR rates, and rechallenge-confirmed immune memory while maintaining systemic immune homeostasis. By delivering decoy resistant IL-18 variant directly to PD-1⁺ T cells, FL116 re-ignites intratumoral cytotoxic immunity and reshapes the TME toward a highly inflamed, effector-dominant state. These results support FL116 as a promising candidate for next-generation cytokine-fusion immunotherapy."

Biomarker • Bispecific • IO biomarker • Tumor microenvironment • Oncology • CD8 • GZMB • IFNG • IL18 • TNS3

Forlong Biotechology to Present Preclinical Data from…FL116, a PD-1/interleukin-18 (IL-18) bispecific antibody, at the 2026 AACR Annual Meeting (Businesswire) - "Poster 1777 showed FL116 achieved potent anti-tumor activities and rechallenge-confirmed immune memory while maintaining systemic immune homeostasis in multiple tumor models, and re-ignited intratumoral cytotoxic immunity while reshaping the TME toward a highly inflamed, effector-dominant state."

Preclinical • Solid Tumor